HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

FDA

Regulatory intelligence
FDAapproval84% confidence

FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

Source: FDA

Why This Matters

Why this matters: illustrates how regulators handled a comparable approval decision relevant to veterinary pharmaceutical companies; the same agency is already in play for this signal, so precedent weight is higher.

Regulatory Analysis

Supporting Context

Therapeutic area
Veterinary Medicine · Parasitology
Sub-indication
General

Related signal: FDA Grants EUA for Ivermectin Liquid to Prevent New World Screwworm in Horses

Source

View source document

Related Signal

Open signal — FDA Grants EUA for Ivermectin Liquid to Prevent New World Screwworm in Horses
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.